BICO Group AB

BICO

Equity

ISIN SE0013647385 / Valor 51871100

NASDAQ Nordic Exchange Stockholm, Equities (2025-10-17)

SEK 23.46-2.09%

BICO Group AB
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

BICO Group AB is a biotechnology company that specializes in providing innovative solutions for laboratory automation. The company focuses on enabling end-to-end lab automation, which involves streamlining and integrating various laboratory processes to enhance efficiency and accuracy. BICO has restructured its business to emphasize Lab Automation as a standalone business area, highlighting its commitment to advancing this sector. The company's offerings are designed to cater to the needs of modern laboratories, aiming to improve workflow and productivity through cutting-edge technology and automation solutions.

Summarized from source with an LLMView SourceSector: Technology

Divestment Strengthens Balance Sheet

BICO Group AB completed the sale of MatTek and Visikol to Sartorius for USD 80 million, enhancing its balance sheet by reducing debt and freeing up capital for strategic investments.

Macroeconomic Headwinds Persist

Persistent macroeconomic challenges, including NIH funding cuts and tariff uncertainties, have hampered demand and delayed capital expenditure investments, contributing to a 23.4% decrease in net sales for Q2 2025.

Mixed Performance in Life Science Solutions

The Life Science Solutions segment saw flat sales in line with industry peers, with SCIENION demonstrating healthy growth and profitability, whereas instrument companies catering to academia experienced a softer market.

Lab Automation Faces Delays

Fewer project starts and delays in the Lab Automation business area negatively impacted the quarter. BICO is implementing leadership and process changes to scale Biosero's operations and capitalize on the growing lab automation market.

Financial Metrics Show Decline

Net sales dropped to SEK 324.2 million, with organic sales growth at -17.0%. The gross margin decreased to 43.9%, and the adjusted EBITDA stood at SEK -48.8 million, reflecting a margin of -15.1%. The company reported a net loss of SEK -181.7 million for the quarter.

Summarized from source with an LLMView Source

Key figures

-43.1%1Y

-28.6%3Y

-88.6%5Y

Performance

65.2%1Y

83.4%3Y

91.2%5Y

Volatility